4.1. Therapeutic indications

Treatment of HIV-1 infection:

Emtricitabine/ Tenofovir disoproxil is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults (see section 5.1)

Emtricitabine/ Tenofovir disoproxil is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years (see section 4.2, 4.4 and 5.1).

Pre-exposure prophylaxis (PrEP):

Emtricitabine/ Tenofovir disoproxil is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk (see sections 4.2,4.4 and 5.1).

4.2. Posology and method of administration

Emtricitabine/ Tenofovir disoproxil should be initiated by a physician experienced in the management of HIV infection.

Posology

Treatment of HIV in adults and adolescents aged 12 years and older, weighing at least 35 kg: One tablet, once daily.

Prevention of HIV in adults and adolescents aged 12 years and older, weighing at least 35 kg: One tablet, once daily.

Separate preparations of emtricitabine and tenofovir disoproxil fumarate are available for treatment of HIV-1 infection if it becomes necessary to discontinue or modify the dose of one of the components of Emtricitabine/ Tenofovir disoproxil. Please refer to the Summary of Product Characteristics for these medicinal products

If a dose of Emtricitabine/ Tenofovir disoproxil is missed within 12 hours of the time it is usually taken, Emtricitabine/ Tenofovir disoproxil should be taken as soon as possible and normal dosing schedule should be resumed. If a dose of Emtricitabine/ Tenofovir disoproxil is missed by more than 12 hours and it is almost time for their next dose, the missed dose should not be taken and the usual dosing schedule should be resumed.

If vomiting occurs within 1 hour of taking Emtricitabine/ Tenofovir disoproxil, another tablet should be taken. If vomiting occurs more than 1 hour after taking Emtricitabine/ Tenofovir disoproxil a second dose should not be taken.

Special populations

Elderly: No dose adjustment is required (see section 5.2).

Renal impairment: Emtricitabine and tenofovir disoproxil are eliminated by renal excretion and the exposure to emtricitabine and tenofovir increases in individuals with renal dysfunction (see section 4.4 and 5.2).

Adults with renal impairment:

Emtricitabine and tenofovir disoproxil should only be used in individuals with creatinine clearance (CrCl) < 80mL/min if the potential benefits are considered to outweigh the potential risks. See Table 1.

Table 1: Dosing recommendations in adults with renal impairment

Treatment of HIV-1 infection

Pre-exposure prophylaxis

Mild renal impairment

(CrCl 50-80 mL/min)

Limited data from clinical studies support once daily dosing of Emtricitabine/ Tenofovir disoproxil (see section 4.4).

Limited data from clinical studies support once daily dosing of Emtricitabine/ Tenofovir disoproxil in HIV-1 uninfected individuals with CrCl 60-80 mL/min. Emtricitabine/ Tenofovir disoproxil is not recommended for use in HIV-1 uninfected individuals with CrCl < 60mL/min as it has not been studied in this population (see sections 4.4 and 5.2).

Moderate renal impairment (CrCl 30-49 mL/min)

Administration of Emtricitabine/ Tenofovir disoproxil every 48 hours is recommended based on modelling of single-dose pharmacokinetic data for emtricitabine and tenofovir disoproxil fumarate in non-HIV infected subjects with varying degrees of renal impairment (see section 4.4).

Emtricitabine/ Tenofovir disoproxil is not recommended for use in this population.

Severe renal impairment

(CrCl <30mL/min) and haemodialysis patients

Emtricitabine/ Tenofovir disoproxil is not recommended because appropriate dose reductions cannot be achieved with the combination tablet.

Emtricitabine/ Tenofovir disoproxil is not recommended for use in this population.

Paediatrics with renal impairment:

Use of Emtricitabine/ Tenofovir disoproxil is not recommended in HIV-1 infected paediatric patients under the age of 18 years with renal impairment (see section 4.4).

Hepatic impairment: No dose adjustment is required in patients with hepatic impairment (see sections 4.4 and 5.2).

Paediatric population: The safety and efficacy of Emtricitabine/ Tenofovir disoproxil in children under the age of 12 years have not been established (see section 5.2).

Method of administration

Oral administration. It is preferable that Emtricitabine/ Tenofovir disoproxil is taken with food.

Emtricitabine/ Tenofovir disoproxil can be disintegrated in approximately 100 ml of water, orange juice or grape juice and taken immediately.

4.3. Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Use of Emtricitabine/ Tenofovir disoproxil for pre-exposure prophylaxis in individuals with unknown or positive HIV-1 status.

4.4. Special warnings and precautions for use

Patients with HIV-1 harbouring mutations

Emtricitabine/ Tenofovir disoproxil should be avoided in antiretroviral-experienced patients with HIV-1 harbouring the K65R mutation (see section 5.1).

Overall HIV-1 infection prevention strategy

Emtricitabine/ Tenofovir disoproxil is not always effective in preventing the acquisition of HIV-1. The time to onset of protection after commencing Emtricitabine/ Tenofovir disoproxil is unknown.

Emtricitabine/ Tenofovir disoproxil should only be used for pre-exposure prophylaxis as part of an overall HIV-1 infection prevention strategy including the use of other HIV-1 prevention measures (e.g. consistent and correct condom use, knowledge of HIV-1 status, regular testing for other sexually transmitted infections).

Risk of resistance with undetected HIV-1 infection:

Emtricitabine/ Tenofovir disoproxil should only be used to reduce the risk of acquiring HIV-1 in individuals confirmed to be HIV negative (see section 4.3). Individuals should be re-confirmed to be HIV-negative at frequent intervals (e.g. at least every 3 months) using a combined antigen/antibody test while taking Emtricitabine/ Tenofovir disoproxil for pre-exposure prophylaxis.

Emtricitabine/ Tenofovir disoproxil alone does not constitute a complete regimen for the treatment of HIV-1 and HIV-1 resistance mutations have emerged in individuals with undetected HIV-1 infection who are only taking Emtricitabine/ Tenofovir disoproxil.

If clinical symptoms consistent with acute viral infection are present and recent (< 1 month) exposures to HIV-1 are suspected, use of Emtricitabine/ Tenofovir disoproxil should be delayed for at least one month and HIV-1 status reconfirmed before starting Emtricitabine/ Tenofovir disoproxil for pre-exposure prophylaxis.

Importance of adherence:

HIV-1 uninfected individuals should be counselled to strictly adhere to the recommended Emtricitabine/ Tenofovir disoproxil dosing schedule. The effectiveness of Emtricitabine/ Tenofovir disoproxil in reducing the risk of acquiring HIV-1 is strongly correlated with adherence as demonstrated by measurable drug levels in blood. (see section 5.1)

Patients with hepatitis B or C virus infection

HIV-1 infected patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions. Physicians should refer to current HIV treatment guidelines for the management of HIV infection in patients co-infected with hepatitis B virus (HBV) or hepatitis C virus (HCV).

The safety and efficacy of Emtricitabine/ Tenofovir disoproxil for PrEP in patients with HBV or HCV infection has not been established.

In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products. See also under Use with ledipasvir and sofosbuvir or sofosbuvir and velpatasvir below.

Tenofovir (disoproxil fumarate) is indicated for the treatment of HBV and emtricitabine has shown activity against HBV in pharmacodynamic studies but the safety and efficacy of Emtricitabine/ Tenofovir disoproxil have not been specifically established in patients with chronic HBV infection.

Discontinuation of Emtricitabine/ Tenofovir disoproxil therapy in patients infected with HBV may be associated with severe acute exacerbations of hepatitis. Patients infected with HBV who discontinue Emtricitabine/ Tenofovir disoproxil should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. If appropriate, resumption of hepatitis B therapy may be warranted. In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.

Liver disease

The safety and efficacy of Emtricitabine/ Tenofovir disoproxil have not been established in patients with significant underlying liver disorders. The pharmacokinetics of tenofovir has been studied in patients with hepatic impairment and no dose adjustment is required. The pharmacokinetics of emtricitabine has not been studied in patients with hepatic impairment. Based on minimal hepatic metabolism and the renal route of elimination for emtricitabine, it is unlikely that a dose adjustment would be required for Emtricitabine/ Tenofovir disoproxil in patients with hepatic impairment (see section 4.2 and 5.2).

HIV-1infected patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.

Renal and bone effects in adults

Renal effects

Emtricitabine and tenofovir are primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion. Renal failure, renal impairment, elevated creatinine, hypophosphataemia and proximal tubulopathy (including Fanconi syndrome) have been reported with the use of tenofovir disoproxil fumarate (see section 4.8).

Renal monitoring

Prior to initiating Emtricitabine/ Tenofovir disoproxil for the treatment of HIV-1 infection or for use in pre-exposure prophylaxis, it is recommended that creatinine clearance is calculated in all individuals.

In individuals without risk factors for renal disease, it is recommended that renal function (creatinine clearance and serum phosphate) is monitored after two to four weeks of use, after three months of use and every three to six months thereafter.

In individuals at risk for renal disease more frequent monitoring of renal function is required.

See also under Co-administration of other medicinal products below

Renal management in HIV-1 infected patients:

If serum phosphate is < 1.5 mg/dl (0.48 mmol/l) or creatinine clearance is decreased to < 50 ml/min in any patient receiving Emtricitabine/ Tenofovir disoproxil, renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy). Consideration should also be given to interrupting treatment with Emtricitabine/ Tenofovir disoproxil in patients with creatinine clearance decreased to < 50 ml/min or decreases in serum phosphate to < 1.0 mg/dl (0.32 mmol/l). Interrupting treatment with Emtricitabine/ Tenofovir disoproxil should also be considered in case of progressive decline of renal function when no other cause has been identified.

Renal safety with Emtricitabine/ Tenofovir disoproxil has only been studied to a very limited degree in HIV-1 infected patients with impaired renal function (creatinine clearance < 80 ml/min). Dose interval adjustments are recommended for HIV-1 infected patients with creatinine clearance 30-49 ml/min (see section 4.2). Limited clinical study data suggest that the prolonged dose interval is not optimal and could result in increased toxicity and possibly inadequate response. Furthermore, in a small clinical study, a subgroup of patients with creatinine clearance between 50 and 60 ml/min who received tenofovir disoproxil fumarate in combination with emtricitabine every 24 hours had a 2-4-fold higher exposure to tenofovir and worsening of renal function (see section 5.2). Therefore, a careful benefit-risk assessment is needed when Emtricitabine/ Tenofovir disoproxil is used in patients with creatinine clearance < 60 ml/min, and renal function should be closely monitored. In addition, the clinical response to treatment should be closely monitored in patients receiving Emtricitabine/ Tenofovir disoproxil at a prolonged dosing interval. The use of Emtricitabine/ Tenofovir disoproxil is not recommended in patients with severe renal impairment (creatinine clearance < 30 ml/min) and in patients who require haemodialysis since appropriate dose reductions cannot be achieved with the combination tablet (see sections 4.2 and 5.2).

Renal management in PrEP:

Emtricitabine/ Tenofovir disoproxil has not been studied in HIV-1 uninfected individuals with creatinine clearance < 60 mL/min and is therefore not recommended for use in this population. If serum phosphate is < 1.5 mg/dL (0.48 mmol/L) or creatinine clearance is decreased to < 60 mL/min in any individual receiving Emtricitabine/ Tenofovir disoproxil for pre-exposure prophylaxis, renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy). Consideration should be given to interrupting use of with Emtricitabine/ Tenofovir disoproxil in individuals with creatinine clearance decreased to < 60 mL/min or decreases in serum phosphate to < 1.0 mg/dL (0.32 mmol/L). Interrupting use of Emtricitabine/ Tenofovir disoproxil should also be considered in case of progressive decline of renal function when no other cause has been identified.

Bone effects

Bone abnormalities such as osteomalacia which can manifest as persistent or worsening bone pain and, which can infrequently contributing to fractures may be associated with tenofovir disoproxil-induced proximal renal tubulopathy (see section 4.8).

If bone abnormalities are suspected then appropriate consultation should be obtained.

Treatment of HIV-1 infection:

Reductions of bone mineral density (BMD) have been observed with tenofovir disoproxil in randomized controlled clinical trials of duration up to 144 weeks in HIV or HBV-infected patients. These BMD decreases generally improved after treatment discontinuation.

In other studies (prospective and cross-sectional), the most pronounced decreases in BMD were seen in patients treated with tenofovir disoproxil fumarate as part of a regimen containing a boosted protease inhibitor. Overall in view of the bone abnormalities associated with tenofovir disoproxil and the limitations of long term data on the impact of tenofovir disoproxil on bone health and fracture risk, alternative treatment regimens should be considered for patients with osteoporosis or with history of bone fractures.

Emtricitabine/ Tenofovir disoproxil for PrEP:

In clinical studies of HIV-1 uninfected individuals, small decreases in BMD were observed. In a study of 498 men, the mean changes from baseline to week 24 in BMD ranged from - 0.4% to - 1.0% across hip, spine, femoral neck and trochanter in men who received daily Emtricitabine/ Tenofovir disoproxil prophylaxis (n=247) vs. placebo (n=251).

Renal and bone effects in the paediatric population

There are uncertainties associated with the long term renal and bone effects effects of tenofovir disoproxil fumarate during the treatment of HIV-1 infection in the paediatric population. There are no data on the long-term renal and bone effects of Emtricitabine/ Tenofovir disoproxil when used for pre-exposure prophylaxis in uninfected adolescents (see section 5.1). Moreover, the reversibility of renal toxicity after cessation of tenofovir disoproxil for treatment of HIV-1 or after cessation of Emtricitabine/ Tenofovir disoproxil for pre-exposure prophylaxis cannot be fully ascertained.

A multidisciplinary approach is recommended to adequately weigh on a case by case basis the benefit/risk balance of treatment, decide the appropriate monitoring during treatment (including decision for treatment withdrawal) and consider the need for supplementation.

When using Emtricitabine/ Tenofovir disoproxil for pre-exposure prophylaxis individuals should be reassessed at each visit to ascertain whether they remain at high risk of HIV-1 infection. The risk of HIV-1 infection should be balanced against the potential for renal and bone effects with long-term use of Emtricitabine/ Tenofovir disoproxil

Renal effects:

Renal adverse reactions consistent with proximal renal tubulopathy have been reported in HIV-1 infected paediatric patients aged 2 to < 12 years in clinical study GS-US-104-0352 (see sections 4.8 and 5.1).

Renal monitoring

Renal function (creatinine clearance and serum phosphate) should be evaluated prior to treatment of HIV-1 or for pre-exposure prophylaxis, and should be monitored during use as in adults (see above).

Renal management

If serum phosphate is confirmed to be < 3.0 mg/dl (0.96 mmol/l) in any paediatric patient receiving Emtricitabine/ Tenofovir disoproxil, renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy). If renal abnormalities are suspected or detected then consultation with a nephrologist should be obtained to consider interruption of treatment. Interrupting treatment with Emtricitabine/ Tenofovir disoproxil should also be considered in case of progressive decline of renal function when no other cause has been identified.

Co-administration and risk of renal toxicity

The same recommendations apply as in adults (see Co-administration of other medicinal products below)

Renal impairment

The use of Emtricitabine/ Tenofovir disoproxil is not recommended in individuals under the age of 18 years with renal impairment (see section 4.2). Emtricitabine/ Tenofovir disoproxil should not be initiated in paediatric patients with renal impairment and should be discontinued in paediatric patients who develop renal impairment during Emtricitabine/ Tenofovir disoproxil therapy.

Bone effects

Tenofovir disoproxil fumarate may cause a reduction in BMD. The effects of tenofovir disoproxil fumarate-associated changes in BMD on long-term bone health and future fracture risk are currently unknown (see section 5.1).

If bone abnormalities are detected or suspected in peadiatric patients, consultation with an endocrinologist and/or nephrologist should be obtained.

Weight and metabolic parameters

An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Such changes may in part be linked to disease control and life style. For lipids, there is in some cases evidence for a treatment effect, while for weight gain there is no strong evidence relating this to any particular treatment. For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.

Mitochondrial dysfunction following exposure in utero

Nucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine. There have been reports of mitochondrial dysfunction in HIV negative infants exposed in utero and/or postnatally to nucleoside analogues; these have predominantly concerned treatment with regimens containing zidovudine. The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactataemia, hyperlipasaemia). These events are often transitory. Late-onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are transient or permanent is currently unknown. These findings should be considered for any child exposed in utero to nucleos(t)ide analogues, who present with severe clinical findings of unknown etiology, particularly neurologic findings. These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.

Immune Reactivation Syndrome

In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jirovecii pneumonia. Any inflammatory symptoms should be evaluated and treatment instituted when necessary.

Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.

Opportunistic infections

HIV-1 infected Patients receiving Emtricitabine/ Tenofovir disoproxil or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.

Osteonecrosis

Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to CART. Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.

Co-administration of other medicinal products

Use of Emtricitabine/ Tenofovir disoproxil should be avoided with concurrent or recent use of a nephrotoxic medicinal product (see section 4.5). If concomitant use of Emtricitabine/ Tenofovir disoproxil and nephrotoxic agents is unavoidable, renal function should be monitored weekly.

Cases of acute renal failure after initiation of high dose or multiple non-steroidal anti-inflammatory drugs (NSAIDs) have been reported in HIV-1 infected patients treated with tenofovir disoproxil fumarate and with risk factors for renal dysfunction. If Emtricitabine/ Tenofovir disoproxil is co-administered with an NSAID, renal function should be monitored adequately.

A higher risk of renal impairment has been reported in HIV-1 infected patients receiving tenofovir disoproxil fumarate in combination with a ritonavir or cobicistat boosted protease inhibitor. A close monitoring of renal function is required in these patients (see section 4.5). In HIV-1 infected patients with renal risk factors, the co-administration of tenofovir disoproxil fumarate with a boosted protease inhibitor should be carefully evaluated.

Emtricitabine/ Tenofovir disoproxil should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil (as fumarate), tenofovir alafenamide, or other cytidine analogues, such as lamivudine (see section 4.5). Emtricitabine/ Tenofovir disoproxil should not be administered concomitantly with adefovir dipivoxil.

Use with ledipasvir and sofosbuvir, sofosbuvir and velpatasvir or sofosbuvir, velpatasvir and voxilaprevir

Co-administration of tenofovir disoproxil fumarate with ledipasvir/sofosbuvir, sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir has been shown to increase plasma concentrations of tenofovir, especially when used together with an HIV regimen containing tenofovir disoproxil fumarate and a pharmacokinetic enhancer (ritonavir or cobicistat).

The safety of tenofovir disoproxil fumarate when co-administered with ledipasvir/sofosbuvir, sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir and a pharmacokinetic enhancer has not been established. The potential risks and benefits associated with co-administration should be considered, particularly in patients at increased risk of renal dysfunction. Patients receiving ledipasvir/sofosbuvir, sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir concomitantly with tenofovir disoproxil fumarate and a boosted HIV protease inhibitor should be monitored for adverse reactions related to tenofovir disoproxil fumarate.

Co-administration of tenofovir disoproxil fumarate and didanosine:

Co-administration is not recommended (see section 4.5).

Triple nucleoside therapy

There have been reports of a high rate of virological failure and of emergence of resistance at an early stage in HIV-1 infected patients when tenofovir disoproxil fumarate was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen. There is close structural similarity between lamivudine and emtricitabine and similarities in the pharmacokinetics and pharmacodynamics of these two agents. Therefore, the same problems may be seen if Emtricitabine/ Tenofovir disoproxil is administered with a third nucleoside analogue.

Elderly

Emtricitabine/ Tenofovir disoproxil has not been studied in individuals over the age of 65. Individuals over the age of 65 years are more likely to have decreased renal function, therefore caution should be exercised when administering Emtricitabine/ Tenofovir disoproxil to older people.

Excipients

Emtricitabine/ Tenofovir disoproxil contains lactose. Consequently, patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.

4.5. Interaction with other medicinal products and other forms of interaction

Interaction studies have only been performed in adults.

As Emtricitabine/ Tenofovir disoproxil contains emtricitabine and tenofovir disoproxil fumarate, any interactions that have been identified with these agents individually may occur with Emtricitabine/ Tenofovir disoproxil. Interaction studies have only been performed in adults.

The steady-state pharmacokinetics of emtricitabine and tenofovir were unaffected when emtricitabine and tenofovir disoproxil fumarate were administered together versus each medicinal product dosed alone.

In vitro and clinical pharmacokinetic interaction studies have shown the potential for CYP450 mediated interactions involving emtricitabine and tenofovir disoproxil fumarate with other medicinal products is low.

Concomitant use not recommended

Emtricitabine/ Tenofovir disoproxil should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil (as fumarate), tenofovir alafenamide or other cytidine analogues, such as lamivudine (see section 4.4). Emtricitabine/ Tenofovir disoproxil should not be administered concomitantly with adefovir dipivoxil.

Didanosine: The co-administration of Emtricitabine/ Tenofovir disoproxil and didanosine is not recommended (see section 4.4 and Table 2).

Renally eliminated medicinal products: Since emtricitabine and tenofovir are primarily eliminated by the kidneys, co-administration of Emtricitabine/ Tenofovir disoproxil with medicinal products that reduce renal function or compete for active tubular secretion (e.g. cidofovir) may increase serum concentrations of emtricitabine, tenofovir and/or the co-administered medicinal products.

Use of Emtricitabine/ Tenofovir disoproxil should be avoided with concurrent or recent use of a nephrotoxic medicinal product. Some examples include, but are not limited to, aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2 (see section 4.4).

Other interactions

Interactions between the Emtricitabine/ Tenofovir disoproxil or its individual component(s) and other medicinal products, are listed in Table 2 below (increase is indicated as “↑“, decrease as “↓“, no change as “↔“, twice daily as “b.i.d.” and once daily as “q.d.”). If available, 90% confidence intervals are shown in parentheses.

Table 2: Interactions between the Emtricitabine/ Tenofovir disoproxil or its individual component(s) and other medicinal products

Medicinal product by therapeutic areas

Effects on drug levels

Mean percent change in AUC, Cmax, Cmin with 90% confidence intervals if available

(mechanism)

Recommendation concerning co-administration with Emtricitabine/ Tenofovir disoproxil

(emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg)

ANTI-INFECTIVES

Antiretrovirals

Protease inhibitors

Atazanavir/Ritonavir/Tenofovir disoproxil fumarate

(300 mg q.d./100 mg q.d./300 mg q.d.)

Atazanavir:

AUC: ↓ 25% (↓ 42 to ↓ 3)

Cmax: ↓ 28% (↓ 50 to ↑ 5)

Cmin: ↓ 26% (↓ 46 to ↑ 10)

Tenofovir:

AUC: ↑ 37%

Cmax: ↑ 34%

Cmin: ↑ 29%

No dose adjustment is recommended. The increased exposure of tenofovir could potentiate tenofovir associated adverse events, including renal disorders. Renal function should be closely monitored (see section 4.4).

Atazanavir/Ritonavir/Emtricitabine

Interaction not studied.

Darunavir/Ritonavir/Tenofovir disoproxil fumarate

(300 mg q.d./100 mg q.d./300 mg q.d.)

Darunavir:

AUC: ↔

Cmin: ↔

Tenofovir:

AUC: ↑ 22%

Cmin: ↑ 37%

No dose adjustment is recommended. The increased exposure of tenofovir could potentiate tenofovir associated adverse events, including renal disorders. Renal function should be closely monitored (see section 4.4).

Darunavir/Ritonavir/Emtricitabine

Interaction not studied.

Lopinavir/Ritonavir/Tenofovir disoproxil fumarate

(400 mg b.i.d./100 mg b.i.d/300 mg q.d.)

Lopinavir/Ritonavir:

AUC: ↔

Cmax: ↔

Cmin: ↔

Tenofovir:

AUC: ↑ 32% (↑ 25 to ↑ 38)

Cmax: ↔

Cmin: ↑ 51% (↑ 37 to ↑ 66)

No dose adjustment is recommended. The increased exposure of tenofovir could potentiate tenofovir associated adverse events, including renal disorders. Renal function should be closely monitored (see section 4.4).

Lopinavir/Ritonavir/Emtricitabine

Interaction not studied.

NRTIs

Didanosine/Tenofovir disoproxil fumarate

Co-administration of tenofovir disoproxil fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine. .

Co-administration of Emtricitabine/ Tenofovir disoproxil and didanosine is not recommended (see section 4.4).

Increased systemic exposure to didanosine may be increase didanosine-related adverse reactions. Rarely, pancreatitis and lactic acidosis, sometimes fatal, have been reported.

Co-administration of tenofovir disoproxil fumarate and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine. A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil fumarate therapy has been associated with reports of high rates of virological failure within several tested combinations for the treatment of HIV-1 infection

Didanosine/Emtricitabine

Interaction not studied.

Lamivudine/Tenofovir disoproxil fumarate

Lamivudine:

AUC: ↓ 3% (↓ 8% to ↑ 15)

Cmax: ↓ 24% (↓ 44 to ↓ 12)

Cmin: NC

Tenofovir:

AUC: ↓ 4% (↓ 15 to ↑ 8)

Cmax: ↑ 102% (↓ 96 to ↑ 108)

Cmin: NC

Lamivudine and Emtricitabine/Tenofovir disoproxil should not be administered concomitantly (See section 4.4).

Efavirenz/Tenofovir disoproxil fumarate

Efavirenz:

AUC: ↓ 4% (↓ 7 to ↓ 1)

Cmax: ↓ 4% (↓ 9 to ↑ 2)

Cmin: NC

Tenofovir:

AUC: ↓ 1% (↓ 8 to ↑ 6)

Cmax: ↑ 7% (↓ 6 to ↑ 22)

Cmin: NC

No dose adjustment of efavirenz is required.

ANTI-INFECTIVES

Hepatitis B virus (HBV) antiviral agents

Adefovir dipivoxil /Tenofovir disoproxil fumarate

Adefovir dipivoxil:

AUC: ↓ 11% (↓ 14 to ↓ 7)

Cmax: ↓ 7% (↓ 13 to ↓ 0)

Cmin: NC

Tenofovir:

AUC: ↓ 2% (↓ 5 to ↑ 0)

Cmax: ↓ 1% (↓ 7 to ↑ 6)

Cmin: NC

Adefovir dipivoxil and Emtricitabine/ Tenofovir disoproxil should not be administered concomitantly (see section 4.4).

Hepatitis C virus (HCV) antiviral agents

Ledipasvir/Sofosbuvir

(90 mg/400 mg q.d.) +

Atazanavir/Ritonavir

(300 mg q.d./100 mg q.d.) +

Emtricitabine/Tenofovir disoproxil fumarate

(200 mg/300 mg q.d.)1

Ledipasvir:

AUC: ↑ 96% (↑ 74 to ↑ 121)

Cmax: ↑ 68% (↑ 54 to ↑ 84)

Cmin: ↑ 118% (↑ 91 to ↑ 150)

Sofosbuvir:

AUC: ↔

Cmax: ↔

GS-3310072:

AUC: ↔

Cmax: ↔

Cmin: ↑ 42% (↑ 34 to ↑ 49)

Atazanavir:

AUC: ↔

Cmax: ↔

Cmin: ↑ 63% (↑ 45 to ↑ 84)

Ritonavir:

AUC: ↔

Cmax: ↔

Cmin: ↑ 45% (↑ 27 to ↑ 64)

Emtricitabine:

AUC: ↔

Cmax: ↔

Cmin: ↔

Tenofovir:

AUC: ↔

Cmax: ↑ 47% (↑ 37 to ↑ 58)

Cmin: ↑ 47% (↑ 38 to ↑ 57)

Increased plasma concentrations of tenofovir resulting from co-administration of tenofovir disoproxil fumarate, ledipasvir/sofosbuvir and atazanavir/ritonavir may increase adverse reactions related to tenofovir disoproxil fumarate, including renal disorders. The safety of tenofovir disoproxil fumarate when used with ledipasvir/sofosbuvir and a pharmacokinetic enhancer (e.g. ritonavir or cobicistat) has not been established.

The combination should be used with caution with frequent renal monitoring, if other alternatives are not available (see section 4.4).

Ledipasvir/Sofosbuvir

(90 mg/400 mg q.d.) +

Darunavir/Ritonavir

(800 mg q.d./100 mg q.d.) +

Emtricitabine/Tenofovir disoproxil fumarate

(200 mg/300 mg q.d.)1

Ledipasvir:

AUC: ↔

Cmax: ↔

Cmin: ↔

Sofosbuvir:

AUC: ↓ 27% (↓ 35 to ↓ 18)

Cmax: ↓ 37% (↓ 48 to ↓ 25)

GS-3310072:

AUC: ↔

Cmax: ↔

Cmin: ↔

Darunavir:

AUC: ↔

Cmax: ↔

Cmin: ↔

Ritonavir:

AUC: ↔

Cmax: ↔

Cmin: ↑ 48% (↑ 34 to ↑ 63)

Emtricitabine:

AUC: ↔

Cmax: ↔

Cmin: ↔\

Tenofovir:

AUC: ↑ 50% (↑ 42 to ↑ 59)

Cmax: ↑ 64% (↑ 54 to ↑ 74)

Cmin: ↑ 59% (↑ 49 to ↑ 70)

Increased plasma concentrations of tenofovir resulting from co-administration of tenofovir disoproxil fumarate, ledipasvir/sofosbuvir and darunavir/ritonavir may increase adverse reactions related to tenofovir disoproxil fumarate, including renal disorders. The safety of tenofovir disoproxil fumarate when used with ledipasvir/sofosbuvir and a pharmacokinetic enhancer (e.g. ritonavir or cobicistat) has not been established.

The combination should be used with caution with frequent renal monitoring, if other alternatives are not available (see section 4.4).

Ledipasvir/Sofosbuvir

(90 mg/400 mg q.d.) +

Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate

(600 mg/200 mg/300 mg q.d.)

Ledipasvir:

AUC: ↓ 34% (↓ 41 to ↓ 25)

Cmax: ↓ 34% (↓ 41 to ↑ 25)

Cmin: ↓ 34% (↓ 43 to ↑ 24)

Sofosbuvir:

AUC: ↔

Cmax: ↔

GS-3310072:

AUC: ↔

Cmax: ↔

Cmin: ↔

Efavirenz:

AUC: ↔

Cmax: ↔

Cmin: ↔

Emtricitabine:

AUC: ↔

Cmax: ↔

Cmin: ↔

Tenofovir:

AUC: ↑ 98% (↑ 77 to ↑ 123)

Cmax: ↑ 79% (↑ 56 to ↑ 104)

Cmin: ↑ 163% (↑ 137 to ↑ 197)

No dose adjustment is recommended. The increased exposure of tenofovir could potentiate adverse reactions associated with tenofovir disoproxil fumarate, including renal disorders. Renal function should be closely monitored (see section 4.4).

Ledipasvir/Sofosbuvir

(90 mg/400 mg q.d.) +

Emtricitabine/Rilpivirine/ Tenofovir disoproxil fumarate

(200 mg/25 mg/300 mg q.d.)

Ledipasvir:

AUC: ↔

Cmax: ↔

Cmin: ↔

Sofosbuvir:

AUC: ↔

Cmax: ↔

GS-3310072:

AUC: ↔

Cmax: ↔

Cmin: ↔

Emtricitabine:

AUC: ↔

Cmax: ↔

Cmin: ↔

Rilpivirine:

AUC: ↔

Cmax: ↔

Cmin: ↔

Tenofovir:

AUC: ↑ 40% (↑ 31 to ↑ 50)

Cmax: ↔

Cmin: ↑ 91% (↑ 74 to ↑ 110)

No dose adjustment is recommended. The increased exposure of tenofovir could potentiate adverse reactions associated with tenofovir disoproxil fumarate, including renal disorders. Renal function should be closely monitored (see section 4.4).

Ledipasvir/Sofosbuvir

(90 mg/400 mg q.d.) +

Dolutegravir (50 mg q.d.) +

Emtricitabine/Tenofovir disoproxil

fumarate (200 mg/300 mg q.d.)

Sofosbuvir:

AUC: ↔

Cmax: ↔

GS-3310072

AUC: ↔

Cmax: ↔

Cmin: ↔

Ledipasvir:

AUC: ↔

Cmax: ↔

Cmin: ↔

Dolutegravir

AUC: ↔

Cmax: ↔

Cmin: ↔

Emtricitabine:

AUC: ↔

Cmax: ↔

Cmin: ↔

Tenofovir:

AUC: ↑ 65% (↑ 59 to ↑ 71)

Cmax: ↑ 61% (↑ 51 to ↑ 72)

Cmin: ↑ 115% (↑ 105 to ↑ 126)

No dose adjustment is required.

The increased exposure of tenofovir could potentiate adverse reactions associated with tenofovir disoproxil fumarate, including renal disorders. Renal function should be closely monitored (see section 4.4).

Sofosbuvir/Velpatasvir

(400 mg/100 mg q.d.) +

Atazanavir/Ritonavir

(300 mg q.d./100 mg q.d.) +

Emtricitabine/Tenofovir disoproxil fumarate

(200 mg/300 mg q.d.)

Sofosbuvir:

AUC: ↔

Cmax: ↔

GS-3310072:

AUC: ↔

Cmax: ↔

Cmin: ↑ 42% (↑ 37 to ↑ 49)

Velpatasvir:

AUC: ↑ 142% (↑ 123 to ↑ 164)

Cmax: ↑ 55% (↑ 41 to ↑ 71)

Cmin: ↑ 301% (↑ 257 to ↑ 350)

Atazanavir:

AUC: ↔

Cmax: ↔

Cmin: ↑ 39% (↑ 20 to ↑ 61)

Ritonavir:

AUC: ↔

Cmax: ↔

Cmin: ↑ 29% (↑ 15 to ↑ 44)

Emtricitabine:

AUC: ↔

Cmax: ↔

Cmin: ↔

Tenofovir:

AUC: ↔

Cmax: ↑ 55% (↑ 43 to ↑ 68)

Cmin: ↑ 39% (↑ 31 to ↑ 48)

Increased plasma concentrations of tenofovir resulting from co-administration of tenofovir disoproxil fumarate, sofosbuvir/velpatasvir and atazanavir/ritonavir may increase adverse reactions related to tenofovir disoproxil fumarate, including renal disorders. The safety of tenofovir disoproxil fumarate when used with sofosbuvir/velpatasvir and a pharmacokinetic enhancer (e.g. ritonavir or cobicistat) has not been established.

The combination should be used with caution with frequent renal monitoring (see section 4.4).

Sofosbuvir/Velpatasvir

(400 mg/100 mg q.d.) +

Darunavir/Ritonavir

(800 mg q.d./100 mg q.d.) +

Emtricitabine/Tenofovir disoproxil fumarate

(200 mg/300 mg q.d.)

Sofosbuvir:

AUC: ↓ 28% (↓ 34 to ↓ 20)

Cmax: ↓ 38% (↓ 46 to ↓ 29)

GS-3310072:

AUC: ↔

Cmax: ↔

Cmin: ↔

Velpatasvir:

AUC: ↔

Cmax: ↓ 24% (↓ 35 to ↓ 11)

Cmin: ↔

Darunavir:

AUC: ↔

Cmax: ↔

Cmin: ↔

Ritonavir:

AUC: ↔

Cmax: ↔

Cmin: ↔

Emtricitabine:

AUC: ↔

Cmax: ↔

Cmin: ↔

Tenofovir:

AUC: ↑ 39% (↑ 33 to ↑ 44)

Cmax: ↑ 55% (↑ 45 to ↑ 66)

Cmin: ↑ 52% (↑ 45 to ↑ 59)

Increased plasma concentrations of tenofovir resulting from co-administration of tenofovir disoproxil fumarate, sofosbuvir/velpatasvir and darunavir/ritonavir may increase adverse reactions related to tenofovir disoproxil fumarate, including renal disorders. The safety of tenofovir disoproxil fumarate when used with sofosbuvir/velpatasvir and a pharmacokinetic enhancer (e.g. ritonavir or cobicistat) has not been established.

The combination should be used with caution with frequent renal monitoring (see section 4.4).

Sofosbuvir/Velpatasvir

(400 mg/100 mg q.d.) +

Lopinavir/Ritonavir

(800 mg/200 mg q.d.) +

Emtricitabine/Tenofovir disoproxil fumarate

(200 mg/300 mg q.d.)

Sofosbuvir:

AUC: ↓ 29% (↓ 36 to ↓ 22)

Cmax: ↓ 41% (↓ 51 to ↓ 29)

GS-3310072:

AUC: ↔

Cmax: ↔

Cmin: ↔

Velpatasvir:

AUC: ↔

Cmax: ↓ 30% (↓ 41 to ↓ 17)

Cmin: ↑ 63% (↑ 43 to ↑ 85)

Lopinavir:

AUC: ↔

Cmax: ↔

Cmin: ↔

Ritonavir:

AUC: ↔

Cmax: ↔

Cmin: ↔

Emtricitabine:

AUC: ↔

Cmax: ↔

Cmin: ↔

Tenofovir:

AUC: ↔

Cmax: ↑ 42% (↑ 27 to ↑ 57)

Cmin: ↔

Increased plasma concentrations of tenofovir resulting from co-administration of tenofovir disoproxil fumarate, sofosbuvir/velpatasvir and lopinavir/ritonavir may increase adverse reactions related to tenofovir disoproxil fumarate, including renal disorders. The safety of tenofovir disoproxil fumarate when used with sofosbuvir/velpatasvir and a pharmacokinetic enhancer (e.g. ritonavir or cobicistat) has not been established.

The combination should be used with caution with frequent renal monitoring (see section 4.4).

Sofosbuvir/Velpatasvir (400 mg/100 mg q.d.) +

Raltegravir

(400 mg b.i.d) +

Emtricitabine/Tenofovir disoproxil fumarate

(200 mg/300 mg q.d.)

Sofosbuvir:

AUC: ↔

Cmax: ↔

GS-3310072:

AUC: ↔

Cmax: ↔

Cmin: ↔

Velpatasvir:

AUC: ↔

Cmax: ↔

Cmin: ↔

Raltegravir:

AUC: ↔

Cmax: ↔

Cmin: ↓ 21% (↓ 58 to ↑ 48)

Emtricitabine:

AUC: ↔

Cmax: ↔

Cmin: ↔

Tenofovir:

AUC: ↑ 40% (↑ 34 to ↑ 45)

Cmax: ↑ 46% (↑ 39 to ↑ 54)

Cmin: ↑ 70% (↑ 61 to ↑ 79)

No dose adjustment is recommended. The increased exposure of tenofovir could potentiate adverse reactions associated with tenofovir disoproxil fumarate, including renal disorders. Renal function should be closely monitored (see section 4.4).

Sofosbuvir/Velpatasvir

(400 mg/100 mg q.d.) +

Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate

(600 mg/200 mg/300 mg q.d.)

Sofosbuvir:

AUC: ↔

Cmax: ↑ 38% (↑ 14 to ↑ 67)

GS-3310072:

AUC: ↔

Cmax: ↔

Cmin: ↔

Velpatasvir:

AUC: ↓ 53% (↓ 61 to ↓ 43)

Cmax: ↓ 47% (↓ 57 to ↓ 36)

Cmin: ↓ 57% (↓ 64 to ↓ 48)

Efavirenz:

AUC: ↔

Cmax: ↔

Cmin: ↔

Emtricitabine:

AUC: ↔

Cmax: ↔

Cmin: ↔

Tenofovir:

AUC: ↑ 81% (↑ 68 to ↑ 94)

Cmax: ↑ 77% (↑ 53 to ↑ 104)

Cmin: ↑ 121% (↑ 100 to ↑ 143)

Concomitant administration of sofosbuvir/velpatasvir and efavirenz is expected to decrease plasma concentrations of velpatasvir.

Co-administration of sofosbuvir/velpatasvir with efavirenz-containing regimens is not recommended.

Sofosbuvir/Velpatasvir

(400 mg/100 mg q.d.) +

Emtricitabine/Rilpivirine/Tenofovir disoproxil fumarate

(200 mg/25 mg/300 mg q.d.)

Sofosbuvir:

AUC: ↔

Cmax: ↔

GS-3310072:

AUC: ↔

Cmax: ↔

Cmin: ↔

Velpatasvir:

AUC: ↔

Cmax: ↔

Cmin: ↔

Emtricitabine:

AUC: ↔

Cmax: ↔

Cmin: ↔

Rilpivirine:

AUC: ↔

Cmax: ↔

Cmin: ↔

Tenofovir:

AUC: ↑ 40% (↑ 34 to ↑ 46)

Cmax: ↑ 44% (↑ 33 to ↑ 55)

Cmin: ↑ 84% (↑ 76 to ↑ 92)

No dose adjustment is recommended. The increased exposure of tenofovir could potentiate adverse reactions associated with tenofovir disoproxil fumarate, including renal disorders. Renal function should be closely monitored (see section 4.4).

Sofosbuvir/Velpatasvir/ Voxilaprevir (400 mg/100 mg/ 100 mg+100 mg q.d.)3 + Darunavir (800 mg q.d.) + Ritonavir (100 mg q.d.) + Emtricitabine/Tenofovir disoproxil (200 mg/245 mg q.d.)

Sofosbuvir:

AUC: ↔

Cmax: ↓ 30%

Cmin: N/A

GS-3310072:

AUC: ↔

Cmax:↔

Cmin: N/A

Velpatasvir:

AUC: ↔

Cmax: ↔

Cmin: ↔

Voxilaprevir:

AUC: ↑ 143%

Cmax:↑ 72%

Cmin: ↑ 300%

Darunavir:

AUC: ↔

Cmax: ↔

Cmin: ↓ 34%

Ritonavir:

AUC: ↑ 45%

Cmax: ↑ 60%

Cmin: ↔

Emtricitabine:

AUC: ↔

Cmax: ↔

Cmin: ↔

Tenofovir:

AUC: ↑ 39%

Cmax: ↑ 48%

Cmin: ↑ 47%

Increased plasma concentrations of tenofovir resulting from co-administration of tenofovir disoproxil, sofosbuvir/velpatasvir/voxilaprevir and darunavir/ritonavir may increase adverse reactions related to tenofovir disoproxil, including renal disorders. The safety of tenofovir disoproxil when used with sofosbuvir/velpatasvir/voxilaprevir and a pharmacokinetic enhancer (e.g. ritonavir or cobicistat) has not been established.

The combination should be used with caution with frequent renal monitoring (see section 4.4).

Sofosbuvir

(400 mg q.d.) +

Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate

(600 mg/200 mg/300 mg q.d.)

Sofosbuvir:

AUC: ↔

Cmax: ↓ 19% (↓ 40 to ↑ 10)

GS-3310072:

AUC: ↔

Cmax: ↓ 23% (↓ 30 to ↑ 16)

Efavirenz:

AUC: ↔

Cmax: ↔

Cmin: ↔

Emtricitabine:

AUC: ↔

Cmax: ↔

Cmin: ↔

Tenofovir:

AUC: ↔

Cmax: ↑ 25% (↑ 8 to ↑ 45)

Cmin: ↔

No dose adjustment is required.

Ribavirin/Tenofovir disoproxil fumarate

Ribavirin:

AUC: ↑ 26% (↑ 20 to ↑ 32)

Cmax: ↓ 5% (↓ 11 to ↑ 1)

Cmin: NC

No dose adjustment of ribavirin is required.

Herpes virus antiviral agents

Famciclovir/Emtricitabine

Famciclovir:

AUC: ↓ 9% (↓ 16 to ↓ 1)

Cmax: ↓ 7% (↓ 22 to ↑ 11)

Cmin: NC

Emtricitabine:

AUC: ↓ 7% (↓ 13 to ↓ 1)

Cmax: ↓ 11% (↓ 20 to ↑ 1)

Cmin: NC

No dose adjustment of famciclovir is required.

Antimycobacterials

Rifampicin/Tenofovir disoproxil fumarate

Tenofovir:

AUC: ↓ 12% (↓ 16 to ↓ 8)

Cmax: ↓ 16% (↓ 22 to ↓ 10)

Cmin: ↓ 15% (↓ 12 to ↓ 9)

No dose adjustment is required.

ORAL CONTRACEPTIVES

Norgestimate/Ethinyl oestradiol/Tenofovir disoproxil fumarate

Norgestimate:

AUC: ↓ 4% (↓ 32 to ↑ 34)

Cmax: ↓ 5% (↓ 27 to ↑ 24)

Cmin: NC

Ethinyl oestradiol:

AUC: ↓ 4% (↓ 9 to ↑ 0)

Cmax: ↓ 6% (↓ 13 to ↑ 0)

Cmin: ↓ 2% (↓ 9 to ↑ 6)

No dose adjustment of norgestimate/ethinyl oestradiol is required.

MMUNOSUPPRESSANTS

Tacrolimus/Tenofovir disoproxil fumarate/Emtricitabine

Tacrolimus:

AUC: ↑ 4% (↓ 3 to ↑ 11)

Cmax: ↑ 3% (↓ 3 to ↑ 9)

Cmin: NC

Emtricitabine:

AUC: ↓ 5% (↓ 9 to ↓ 1)

Cmax: ↓ 11% (↓ 17 to ↓ 5)

Cmin: NC

Tenofovir:

AUC: ↑ 6% (↓ 1 to ↑ 13)

Cmax: ↑13% (↑ 1 to ↑ 27)

Cmin: NC

No dose adjustment of tacrolimus is required.

NARCOTIC ANALGESICS

Methadone/Tenofovir disoproxil fumarate

Methadone:

AUC: ↑ 5% (↓ 2 to ↑ 13)

Cmax: ↑ 5% (↓ 3 to ↑ 14)

Cmin: NC

No dose adjustment of methadone is required.

NC = not calculated

N/A = not applicable.

1 Data generated from simultaneous dosing with ledipasvir/sofosbuvir. Staggered administration (12 hours apart) provided similar results.

2 The predominant circulating metabolite of sofosbuvir.

3 Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV-infected patients.

4.6. Fertility, pregnancy and lactation

Pregnancy

A large amount of data on pregnant women (more than1,000 pregnancy outcomes) indicate no malformations or foetal/neonatal toxicity associated with emtricitabine and tenofovir disoproxil fumarate. Animal studies on emtricitabine and tenofovir disoproxil fumarate do not indicate reproductive toxicity (see section 5.3). Therefore the use of Emtricitabine/ Tenofovir disoproxil may be considered during pregnancy, if necessary.

Breast-feeding

Emtricitabine and tenofovir have been shown to be excreted in human milk. There is insufficient information on the effects of emtricitabine and tenofovir in newborns/infants. Therefore Emtricitabine/ Tenofovir disoproxil should not be used during breast-feeding.

As a general rule, it is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV to the infant.

Fertility

No human data on the effect of Emtricitabine/ Tenofovir disoproxil are available. Animal studies do not indicate harmful effects of emtricitabine or tenofovir disoproxil fumarate on fertility.

4.7. Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, patients should be informed that dizziness has been reported during treatment with both emtricitabine and tenofovir disoproxil fumarate.

4.8. Undesirable effects

Summary of the safety profile

HIV-1 infection: The most frequently reported adverse reactions considered possibly or probably related to emtricitabine and/or tenofovir disoproxil fumarate were nausea (12%) and diarrhoea (7%) in an open-label randomised clinical trial (GS-01-934, see section 5.1). The safety profile of emtricitabine and tenofovir disoproxil fumarate in this study was consistent with the previous experience with these agents when each was administered with other antiretroviral agents.

Pre-exposure prophylaxis: No new adverse reactions to Emtricitabine/ Tenofovir disoproxil were identified from two randomised placebo-controlled studies (iPrEx, Partners PrEP) in which 2,830 HIV-1 uninfected adults received Emtricitabine/ Tenofovir disoproxil once daily for pre-exposure prophylaxis. Patients were followed for a median of 71 weeks and 87 weeks, respectively. The most frequent adverse reaction reported in the Emtricitabine/ Tenofovir disoproxil group in the iPrEx study was headache (1%).

Tabulated summary of adverse reactions

The adverse reactions considered at least possibly related to treatment with the components of Emtricitabine/ Tenofovir disoproxil from clinical trial and post-marketing experience in HIV-1 infected patients are listed in Table 3, below, by body system organ class and frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) or rare (≥ 1/10,000 to < 1/1,000).

Table 3: Tabulated summary of adverse reactions associated with the individual components of Emtricitabine/ Tenofovir disoproxil based on clinical study and post-marketing experience

Frequency

Emtricitabine

Tenofovir disoproxil fumarate

Blood and lymphatic system disorders:

Common:

neutropenia

Uncommon:

anaemia2

Immune system disorders:

Common:

allergic reaction

Metabolism and nutrition disorders:

Very common:

Hypophosphataemia1

Common:

hyperglycaemia, hypertriglyceridaemia

Uncommon:

hypokalaemia1

Rare:

lactic acidosis

Psychiatric disorders:

Common:

insomnia, abnormal dreams

Nervous system disorders:

Very common:

headache

dizziness

Common:

dizziness

headache

Gastrointestinal disorders:

Very common:

diarrhoea, nausea

diarrhoea, vomiting, nausea

Common:

elevated amylase including elevated pancreatic amylase, elevated serum lipase, vomiting, abdominal pain, dyspepsia

abdominal pain, abdominal distension, flatulence

Uncommon:

pancreatitis

Hepatobiliary disorders:

Common:

elevated serum aspartate aminotransferase (AST) and/or elevated serum alanine aminotransferase (ALT), hyperbilirubinaemia

increased transaminases

Rare:

hepatic steatosis, hepatitis

Skin and subcutaneous tissue disorders:

Very common:

rash

Common:

vesiculobullous rash, pustular rash, maculopapular rash, rash, pruritus, urticaria, skin discolouration (increased pigmentation)2

Uncommon:

Angioedema3

Rare:

angioedema

Musculoskeletal and connective tissue disorders:

Very common:

elevated creatine kinase

Common:

bone mineral density decreased

Uncommon:

rhabdomyolysis1, muscular weakness1

Rare:

osteomalacia (manifested as bone pain and infrequently contributing to fractures)1,3, myopathy1

Renal and urinary disorders:

Uncommon:

increased creatinine, proteinuria, proximal renal tubulopathy including Fanconi syndrome

Rare:

renal failure (acute and chronic), acute tubular necrosis, nephritis (including acute interstitial nephritis)3, nephrogenic diabetes insipidus

General disorders and administration site conditions:

Very common:

asthenia

Common:

pain, asthenia

1 This adverse reaction may occur as a consequence of proximal renal tubulopathy. It is not considered to be causally associated with tenofovir disoproxil fumarate in the absence of this condition.

2 Anaemia was common and skin discolouration (increased pigmentation) was very common when emtricitabine was administered to paediatric patients.

3 This adverse reaction was identified through post-marketing surveillance but not observed in randomised controlled clinical trials in adults or paediatric HIV clinical trials for emtricitabine or in randomised controlled clinical trials or the tenofovir disoproxil fumarate expanded access program for tenofovir disoproxil fumarate. The frequency category was estimated from a statistical calculation based on the total number of patients exposed to emtricitabine in randomised controlled clinical trials (n = 1,563) or tenofovir disoproxil fumarate in randomised controlled clinical trials and the expanded access program (n = 7,319).

Description of selected adverse reactions

Renal impairment: As Emtricitabine/ Tenofovir A disoproxil may cause renal damage monitoring of renal function is recommended (see sections 4.4). Proximal renal tubulopathy generally resolved or improved after tenofovir disoproxil fumarate discontinuation. However, in some HIV-1 infected patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil fumarate discontinuation. Patients at risk of renal impairment (such as patients with baseline renal risk factors, advanced HIV disease, or patients receiving concomitant nephrotoxic medications) are at increased risk of experiencing incomplete recovery of renal function despite tenofovir disoproxil fumarate discontinuation (see section 4.4).

Lactic acidosis:Cases of lactic acidosis have been reported with tenofovir disoproxil alone or in combination with otherantiretrovirals. Patients with predisposing factors such as patients with decompensated liver disease, or patientsreceiving concomitant medications known to induce lactic acidosis are at increased risk of experiencing severe lacticacidosis during tenofovir disoproxil treatment, including fatal outcomes.

Metabolic parameters: Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4).

Immune Reactivation Syndrome: In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves' disease) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).

Osteonecrosis: Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to CART. The frequency of this is unknown (see section 4.4).

Paediatric population

Assessment of adverse reactions related to emtricitabine is based on experience in three paediatric studies (n = 169) where treatment-naïve (n = 123) and treatment-experienced (n = 46) paediatric HIV infected patients aged 4 months to 18 years were treated with emtricitabine in combination with other antiretroviral agents. In addition to the adverse reactions reported in adults, anaemia (9.5%) and skin discolouration (31.8%) occurred more frequently in clinical trials in paediatric patients than in adults (see section 4.8, Tabulated summary of adverse reactions).

Assessment of adverse reactions related to tenofovir disoproxil fumarate is based on two randomized trials (studies GS-US 104-0321 and GS-US-104-0352) in 184 HIV-1 infected paediatric patients (aged 2 to < 18 years) who received treatment with tenofovir disoproxil fumarate (n = 93) or placebo/active comparator (n = 91) in combination with other antiretroviral agents for 48 weeks (see section 5.1). The adverse reactions observed in paediatric patients who received treatment with tenofovir disoproxil fumarate were consistent with those observed in clinical studies of tenofovir disoproxil fumarate in adults (see section 4.8 Tabulated summary of adverse reactions and 5.1).

Reductions in BMD have been reported in paediatric patients. In HIV-1 infected adolescents (aged 12 to < 18 years), the BMD Z-scores observed in subjects who received tenofovir disoproxil fumarate were lower than those observed in subjects who received placebo. In HIV-1 infected children (aged 2 to 15 years), the BMD Z-scores observed in subjects who switched to tenofovir disoproxil fumarate were lower than those observed in subjects who remained on their stavudine- or zidovudine-containing regimen (see sections 4.4 and 5.1).

In study GS-US-104-0352, 89 paediatric patients with a median age of 7 years (range 2 to 15 years) were exposed to tenofovir disoproxil fumarate for a median of 331 weeks. Eightof the 89 patients (9.0%) discontinued study drug due to renal adverse events. Five subjects (5.6%) had laboratory findings clinically consistent with proximal renal tubulopathy, 4 of whom discontinued tenofovir disoproxil therapy. Seven patients had estimated glomerular filtration rate (GFR) values between 70 and 90 mL/min/1.73 m2. Among them, 3 patients experienced a clinically meaningful decline in estimated GFR during therapy which improved after discontinuation of tenofovir disoproxil fumarate.

Other special population(s)

Individuals with renal impairment: Since tenofovir disoproxil fumarate can cause renal toxicity, close monitoring of renal function is recommended in any patient with renal impairment treated with Emtricitabine/ Tenofovir disoproxil (see sections 4.2, 4.4 and 5.2). The use of Emtricitabine/ Tenofovir disoproxil is not recommended in individuals under the age of 18 years with renal impairment (see sections 4.2 and 4.4).

HIV/HBV or HCV co-infected patients: The adverse reaction profile of emtricitabine and tenofovir disoproxil fumarate in a limited number of HIV-infected patients in study GS-01-934 who were co-infected with HBV (n=13) or HCV (n=26) was similar to that observed in patients infected with HIV without co-infection. However, as would be expected in this patient population, elevations in AST and ALT occurred more frequently than in the general HIV infected population.

Exacerbations of hepatitis after discontinuation of treatment: In HBV infected patients, clinical and laboratory evidence of hepatitis have occurred after discontinuation of treatment (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

If overdose occurs the individual must be monitored for evidence of toxicity (see section 4.8), and standard supportive treatment applied as necessary.

Up to 30% of the emtricitabine dose and approximately 10% of the tenofovir dose can be removed by haemodialysis. It is not known whether emtricitabine or tenofovir can be removed by peritoneal dialysis.